INTRODUCTION: To investigate whether baseline levels of anti-citrullinated protein antibody (ACPA) or IgM rheumatoid factor (IgM-RF) and changes in the year thereafter are associated with disease activity, functional and radiographic outcome in early arthritis patients, and provide additional information over baseline autoantibody status. METHODS: In 545 early arthritis patients ACPA and IgM-RF levels, disease activity (DAS28), the Health Assessment Questionnaire (HAQ) and Sharp/Van der Heijde Score (SHS) were assessed annually. Baseline status, levels and first-year changes of the autoantibodies were associated with these measures at the two-year follow-up and sub-analysed according to autoantibody status. RESULTS: The mean age was 52.7 years, 69% was female, at baseline 56% was ACPA positive, 47% IgM-RF positive. At the two-year follow-up the mean DAS28 was 2.88, and the median HAQ and SHS were 0.38 and 1, respectively. At one year, ACPA and IgM-RF levels had decreased by 31% and 56%, respectively. A switch from negative to positive occurred in 2% for ACPA and 3% for IgM-RF. Positive ACPA and RF status were both associated with SHS at two years (P < 0.001), but baseline levels only showed a minor correlation of ACPA with DAS28 and HAQ at two years. Level changes were not associated with the outcome parameters. CONCLUSIONS: Baseline levels and first-year changes of ACPA and IgM-RF are hardly associated with outcome after two years. Seroconversion seldom occurs. Therefore, it does not appear useful to repeat ACPA or IgM-RF measurements.
INTRODUCTION: To investigate whether baseline levels of anti-citrullinated protein antibody (ACPA) or IgM rheumatoid factor (IgM-RF) and changes in the year thereafter are associated with disease activity, functional and radiographic outcome in early arthritispatients, and provide additional information over baseline autoantibody status. METHODS: In 545 early arthritispatientsACPA and IgM-RF levels, disease activity (DAS28), the Health Assessment Questionnaire (HAQ) and Sharp/Van der Heijde Score (SHS) were assessed annually. Baseline status, levels and first-year changes of the autoantibodies were associated with these measures at the two-year follow-up and sub-analysed according to autoantibody status. RESULTS: The mean age was 52.7 years, 69% was female, at baseline 56% was ACPA positive, 47% IgM-RF positive. At the two-year follow-up the mean DAS28 was 2.88, and the median HAQ and SHS were 0.38 and 1, respectively. At one year, ACPA and IgM-RF levels had decreased by 31% and 56%, respectively. A switch from negative to positive occurred in 2% for ACPA and 3% for IgM-RF. Positive ACPA and RF status were both associated with SHS at two years (P < 0.001), but baseline levels only showed a minor correlation of ACPA with DAS28 and HAQ at two years. Level changes were not associated with the outcome parameters. CONCLUSIONS: Baseline levels and first-year changes of ACPA and IgM-RF are hardly associated with outcome after two years. Seroconversion seldom occurs. Therefore, it does not appear useful to repeat ACPA or IgM-RF measurements.
Authors: N del Val del Amo; R Ibanez Bosch; C Fito Manteca; R Gutierrez Polo; E Loza Cortina Journal: Clin Exp Rheumatol Date: 2006 May-Jun Impact factor: 4.473
Authors: E Berglin; T Johansson; U Sundin; E Jidell; G Wadell; G Hallmans; S Rantapää-Dahlqvist Journal: Ann Rheum Dis Date: 2005-09-21 Impact factor: 19.103
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: Louise M A Jansen; Dirkjan van Schaardenburg; Irene van der Horst-Bruinsma; Rob J van der Stadt; Margret H M T de Koning; Ben A C Dijkmans Journal: J Rheumatol Date: 2003-08 Impact factor: 4.666
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-02
Authors: O Meyer; C Labarre; M Dougados; Ph Goupille; A Cantagrel; A Dubois; P Nicaise-Roland; J Sibilia; B Combe Journal: Ann Rheum Dis Date: 2003-02 Impact factor: 19.103
Authors: Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes Journal: Nat Rev Rheumatol Date: 2018-02-08 Impact factor: 20.543
Authors: Maria D Mjaavatten; Désirée van der Heijde; Till Uhlig; Anne J Haugen; Halvor Nygaard; Göran Sidenvall; Knut Helgetveit; Tore K Kvien Journal: Arthritis Res Ther Date: 2010-05-05 Impact factor: 5.156
Authors: René Pfeifle; Tobias Rothe; Natacha Ipseiz; Hans U Scherer; Stephan Culemann; Ulrike Harre; Jochen A Ackermann; Martina Seefried; Arnd Kleyer; Stefan Uderhardt; Benjamin Haugg; Axel J Hueber; Patrick Daum; Gordon F Heidkamp; Changrong Ge; Sybille Böhm; Anja Lux; Wolfgang Schuh; Iryna Magorivska; Kutty S Nandakumar; Erik Lönnblom; Christoph Becker; Diana Dudziak; Manfred Wuhrer; Yoann Rombouts; Carolien A Koeleman; René Toes; Thomas H Winkler; Rikard Holmdahl; Martin Herrmann; Stephan Blüml; Falk Nimmerjahn; Georg Schett; Gerhard Krönke Journal: Nat Immunol Date: 2016-11-07 Impact factor: 25.606
Authors: Marian L Burr; Sebastien Viatte; Marwan Bukhari; Darren Plant; Deborah P Symmons; Wendy Thomson; Anne Barton Journal: Arthritis Res Ther Date: 2012-05-09 Impact factor: 5.156